New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:13 EDTMGNXMacroGenics price target raised to $51 from $35 at Stifel
Stifel increased its price target on MacroGenics as the firm thinks the company is uniquely positioned to benefit from investor enthusiasm for targeted combination therapy in the immuno-oncology space. The firm believes the company has best-in-class technology, while recent data has increased Stifel's confidence in the company's approach. It keeps a Buy rating on the shares.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:47 EDTMGNXMacroGenics has compelling pipeline opportunities, says Roth Capital
Subscribe for More Information
November 18, 2014
07:20 EDTMGNXEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 12, 2014
11:17 EDTMGNXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:21 EDTMGNXMacroGenics strategic change positive, says Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use